drugset / Trial / NCT01711671
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients
Timeline
- Start
- 2013-05
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DKN-01 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 600 mg | Intravenous |
| Comparator | Dexamethasone | Small molecule | — | — |
| Comparator | Lenalidomide | Other / unclassified | — | — |